All the described evidence suggests that when developing anti-cancer treatments targeting single components of the P2X7/CD39/CD73/A2AR axis, scientists should consider their effects on the other members of the pathway that might reinforce or impair the efficacy of single protein-targeting drugs. Here, ADORA2A is linked to cancer.